DK3141548T3 - Fremgangsmåder og mellemprodukter til fremstilling af azaindoler - Google Patents

Fremgangsmåder og mellemprodukter til fremstilling af azaindoler Download PDF

Info

Publication number: DK3141548T3
Authority: DK; Denmark
Prior art keywords: azaindoles; intermediates; preparation; methods
Prior art date: 2011-07-05

Application number

DK16190960.1T

Other languages

English (en)

Inventor

Gerald J Tanoury

Young Chun Jung

Derek Magdziak

Adam Looker

Billie J Kline

Olmo Beatriz Dominguez

Václav Jurcík

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-05

Filing date

2012-07-03

Publication date

2020-07-06

2012-07-03 Application filed by Vertex Pharma filed Critical Vertex Pharma

2020-07-06 Application granted granted Critical

2020-07-06 Publication of DK3141548T3 publication Critical patent/DK3141548T3/da

Links

125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 title 1
239000000543 intermediate Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Steroid Compounds (AREA)

DK16190960.1T 2011-07-05 2012-07-03 Fremgangsmåder og mellemprodukter til fremstilling af azaindoler DK3141548T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161504351P	2011-07-05	2011-07-05
US201261636296P	2012-04-20	2012-04-20
EP12735411.6A EP2729465A2 (en)	2011-07-05	2012-07-03	Processes and intermediates for producing azaindoles

Publications (1)

Publication Number	Publication Date
DK3141548T3 true DK3141548T3 (da)	2020-07-06

Family

ID=46513874

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16190960.1T DK3141548T3 (da)	2011-07-05	2012-07-03	Fremgangsmåder og mellemprodukter til fremstilling af azaindoler

Country Status (19)

Country	Link
US (5)	US8513414B2 (da)
EP (2)	EP3141548B9 (da)
JP (3)	JP2014520815A (da)
KR (1)	KR20140058547A (da)
CN (2)	CN106432311A (da)
AR (1)	AR087069A1 (da)
AU (1)	AU2012279046B2 (da)
BR (1)	BR112014000115A2 (da)
CA (1)	CA2839937C (da)
DK (1)	DK3141548T3 (da)
ES (1)	ES2804528T3 (da)
MX (1)	MX2013015147A (da)
NZ (2)	NZ714502A (da)
PL (1)	PL3141548T3 (da)
PT (1)	PT3141548T (da)
RU (1)	RU2014103806A (da)
TW (1)	TW201321378A (da)
WO (1)	WO2013006634A2 (da)
ZA (1)	ZA201400049B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2364340T3 (es) *	2004-03-30	2011-08-31	Vertex Pharmaceuticals Incorporated	Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
LT3141252T (lt)	2009-06-17	2018-11-12	Vertex Pharmaceuticals Inc.	Gripo virusų replikacijos inhibitoriai
NZ714502A (en) *	2011-07-05	2017-04-28	Vertex Pharma	Processes and intermediates for producing azaindoles
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
WO2014201332A1 (en)	2013-06-14	2014-12-18	Vertex Pharmaceuticals Incorporated	Pharmaceutical combinations useful for treating rheumatoid arthritis
MX2016002176A (es)	2013-08-22	2016-06-23	Vertex Pharma	Azaindoles enriquecidos isotopicamente.
US9296727B2 (en)	2013-10-07	2016-03-29	Vertex Pharmaceuticals Incorporated	Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
LT3068776T (lt)	2013-11-13	2019-08-12	Vertex Pharmaceuticals Incorporated	Gripo virusų replikacijos inhibitoriai
JP6618901B2 (ja)	2013-11-13	2019-12-11	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	インフルエンザウイルスの複製の阻害剤を調製する方法
EP3294735B8 (en)	2015-05-13	2022-01-05	Vertex Pharmaceuticals Incorporated	Inhibitors of influenza viruses replication
EP3294717B1 (en)	2015-05-13	2020-07-29	Vertex Pharmaceuticals Inc.	Methods of preparing inhibitors of influenza viruses replication
SG11201804225PA (en) *	2015-12-09	2018-06-28	Sunshine Lake Pharma Co Ltd	Inhibitors of influenza virus replication, application methods and uses thereof
CN105523986A (zh) *	2015-12-30	2016-04-27	江汉大学	一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
MX375720B (es) *	2016-09-09	2025-03-04	Hoffmann La Roche	Proceso para preparacion de 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-beta;3',4'-d]pirrol.
PL3558321T3 (pl)	2016-12-23	2023-10-23	Felicitex Therapeutics, Inc.	Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b
CA3123985A1 (en) *	2018-12-24	2020-07-02	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
CN113121452A (zh) *	2021-05-10	2021-07-16	甘肃堡昌化工有限公司	一种硫酸法尿嘧啶的精制工艺
CN113851244A (zh) *	2021-09-18	2021-12-28	浙江爱索拓科技有限公司	一种含放射性同位素碳-14废水的处理方法
CN113896716A (zh) *	2021-10-27	2022-01-07	浙江爱索拓科技有限公司	一种放射性同位素碳-14双标记甲磺酸伏美替尼合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9721437D0 (en)	1997-10-10	1997-12-10	Glaxo Group Ltd	Heteroaromatic compounds and their use in medicine
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
AU3704101A (en)	2000-02-17	2001-08-27	Amgen Inc	Kinase inhibitors
AR031130A1 (es) *	2000-09-20	2003-09-10	Abbott Lab	N-acilsulfonamidas promotoras de la apoptosis
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
US7304061B2 (en)	2002-04-26	2007-12-04	Vertex Pharmaceuticals Incorporated	Heterocyclic inhibitors of ERK2 and uses thereof
US7429609B2 (en)	2002-05-31	2008-09-30	Eisai R & D Management Co., Ltd.	Pyrazole compound and medicinal composition containing the same
JP2007507529A (ja) *	2003-09-30	2007-03-29	サイオス・インコーポレーテツド	複素環式アミドおよびスルホンアミド
SG149879A1 (en)	2004-01-30	2009-02-27	Nagase & Co Ltd	OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING α - AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME
UA87494C2 (en) *	2004-03-30	2009-07-27	Вертекс Фармасьютикалс Инкорпорейтед	Azaindoles useful as inhibitors of jak and other protein kinases
ES2364340T3 (es)	2004-03-30	2011-08-31	Vertex Pharmaceuticals Incorporated	Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
WO2006038001A1 (en) *	2004-10-06	2006-04-13	Celltech R & D Limited	Aminopyrimidine derivatives as jnk inhibitors
EP2354140A1 (en)	2005-05-20	2011-08-10	Vertex Pharmaceuticals Incorporated	Pyrrolopyridines useful as inhibitors of protein kinase
UA95940C2 (uk)	2006-01-17	2011-09-26	Вертекс Фармасьютикалс Інкорпорейтед	Азаіндоли як інгібітори кіназ януса
CN101374839A (zh) *	2006-01-17	2009-02-25	沃泰克斯药物股份有限公司	适用作詹纳斯激酶抑制剂的吖吲哚类
EP2038272B8 (en) *	2006-06-30	2013-10-23	Sunesis Pharmaceuticals, Inc.	Pyridinonyl pdk1 inhibitors
EP2050749B1 (en) *	2006-08-08	2017-11-22	Chugai Seiyaku Kabushiki Kaisha	Pyrimidine derivative as pi3k inhibitor and use thereof
CN101646671A (zh)	2006-12-14	2010-02-10	弗特克斯药品有限公司	用作蛋白激酶抑制剂的化合物
CN101910150B (zh) *	2007-11-05	2013-09-18	诺瓦提斯公司	作为cetp抑制剂、可用于治疗疾病如高脂血症或动脉硬化的4-苄基氨基-1-羧基酰基哌啶衍生物
JP5368485B2 (ja) *	2008-02-25	2013-12-18	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼインヒビター
LT3141252T (lt) *	2009-06-17	2018-11-12	Vertex Pharmaceuticals Inc.	Gripo virusų replikacijos inhibitoriai
NZ714502A (en) *	2011-07-05	2017-04-28	Vertex Pharma	Processes and intermediates for producing azaindoles
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
MX2014005565A (es)	2011-11-07	2014-05-30	Vertex Pharma	Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos.
MX2016002176A (es)	2013-08-22	2016-06-23	Vertex Pharma	Azaindoles enriquecidos isotopicamente.

2012
- 2012-07-03 NZ NZ714502A patent/NZ714502A/en not_active IP Right Cessation
- 2012-07-03 CN CN201610811795.3A patent/CN106432311A/zh active Pending
- 2012-07-03 MX MX2013015147A patent/MX2013015147A/es not_active Application Discontinuation
- 2012-07-03 JP JP2014519264A patent/JP2014520815A/ja not_active Withdrawn
- 2012-07-03 ES ES16190960T patent/ES2804528T3/es active Active
- 2012-07-03 KR KR1020147003091A patent/KR20140058547A/ko not_active Withdrawn
- 2012-07-03 RU RU2014103806/04A patent/RU2014103806A/ru not_active Application Discontinuation
- 2012-07-03 EP EP16190960.1A patent/EP3141548B9/en active Active
- 2012-07-03 CA CA2839937A patent/CA2839937C/en active Active
- 2012-07-03 BR BR112014000115A patent/BR112014000115A2/pt not_active IP Right Cessation
- 2012-07-03 CN CN201280036682.0A patent/CN103702998A/zh active Pending
- 2012-07-03 AU AU2012279046A patent/AU2012279046B2/en not_active Ceased
- 2012-07-03 DK DK16190960.1T patent/DK3141548T3/da active
- 2012-07-03 WO PCT/US2012/045431 patent/WO2013006634A2/en not_active Ceased
- 2012-07-03 US US13/541,504 patent/US8513414B2/en not_active Expired - Fee Related
- 2012-07-03 NZ NZ619699A patent/NZ619699A/en not_active IP Right Cessation
- 2012-07-03 PT PT161909601T patent/PT3141548T/pt unknown
- 2012-07-03 PL PL16190960T patent/PL3141548T3/pl unknown
- 2012-07-03 EP EP12735411.6A patent/EP2729465A2/en not_active Withdrawn
- 2012-07-04 TW TW101124076A patent/TW201321378A/zh unknown
- 2012-07-05 AR ARP120102438A patent/AR087069A1/es unknown
2013
- 2013-07-12 US US13/940,421 patent/US8796453B2/en not_active Expired - Fee Related
2014
- 2014-01-06 ZA ZA2014/00049A patent/ZA201400049B/en unknown
- 2014-06-25 US US14/314,158 patent/US8946425B2/en active Active
- 2014-12-15 US US14/570,044 patent/US9090614B2/en not_active Expired - Fee Related
2015
- 2015-06-17 US US14/741,499 patent/US20150284388A1/en not_active Abandoned
2016
- 2016-07-22 JP JP2016144361A patent/JP2017002067A/ja not_active Withdrawn
2018
- 2018-07-19 JP JP2018135847A patent/JP6761448B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20150099884A1 (en)	2015-04-09
PT3141548T (pt)	2020-07-10
AU2012279046B2 (en)	2017-08-31
ES2804528T3 (es)	2021-02-08
EP3141548B1 (en)	2020-04-08
WO2013006634A2 (en)	2013-01-10
EP3141548B9 (en)	2020-08-12
JP2017002067A (ja)	2017-01-05
US8946425B2 (en)	2015-02-03
BR112014000115A2 (pt)	2016-10-04
US9090614B2 (en)	2015-07-28
MX2013015147A (es)	2014-03-27
KR20140058547A (ko)	2014-05-14
ZA201400049B (en)	2015-04-29
US8796453B2 (en)	2014-08-05
NZ714502A (en)	2017-04-28
WO2013006634A9 (en)	2013-03-21
US8513414B2 (en)	2013-08-20
EP2729465A2 (en)	2014-05-14
RU2014103806A (ru)	2015-08-10
JP6761448B2 (ja)	2020-09-23
AU2012279046A1 (en)	2014-01-23
TW201321378A (zh)	2013-06-01
US20130102782A1 (en)	2013-04-25
US20150284388A1 (en)	2015-10-08
US20140309421A1 (en)	2014-10-16
JP2014520815A (ja)	2014-08-25
US20130303764A1 (en)	2013-11-14
WO2013006634A3 (en)	2013-05-10
CA2839937C (en)	2020-11-03
JP2018162314A (ja)	2018-10-18
EP3141548A1 (en)	2017-03-15
CN106432311A (zh)	2017-02-22
AR087069A1 (es)	2014-02-12
CN103702998A (zh)	2014-04-02
NZ619699A (en)	2016-03-31
PL3141548T3 (pl)	2020-09-07
CA2839937A1 (en)	2013-01-10

Publication	Publication Date	Title
DK3141548T3 (da)	2020-07-06	Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK3238709T3 (da)	2020-09-28	Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2739293T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2914627T3 (da)	2021-07-12	Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK2768524T3 (da)	2022-07-04	PD-L1-baseret immunterapi
DK2553113T3 (da)	2022-01-24	FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
CO6821892A2 (es)	2013-12-31	Anticuerpos anti-angptl3 y usos de los mismos
DK3556774T3 (da)	2024-03-25	Anti-CD40-antistoffer og anvendelser deraf
DK2675827T3 (da)	2020-09-07	Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
HRP20180571T1 (hr)	2018-05-18	Polipeptidiantitijela koji antagoniziraju cd40
DK2766392T3 (da)	2019-10-07	Fremgangsmåde til oprensning af antistoffer
DK2683731T3 (da)	2019-06-11	C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
HUE052485T2 (hu)	2021-05-28	RNA készítmény immunterápiára
DK2768321T3 (da)	2020-08-31	Fremgangsmåder og sammensætninger til induktion af mæthed
HUE037048T2 (hu)	2018-08-28	Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
DK2718404T3 (da)	2021-04-26	Fremgangsmåde til fremstilling af flydende carbonhydrider
CO6960555A2 (es)	2014-05-30	Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
DK2785801T4 (da)	2019-10-07	Fremgangsmåde til formindskelse af isdannelse på et underlag
DK3656758T3 (da)	2024-04-22	Mellemprodukter til fremstilling af c-terminale hsp90-inhibitorer
DK3050883T3 (da)	2020-05-25	Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
DK2627656T3 (da)	2014-09-08	Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
BR112013025299A2 (pt)	2016-12-13	conjunto de ancoragem
DK2771022T3 (da)	2020-09-28	Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
DK2661274T3 (da)	2019-08-26	Sammensætninger og fremgangsmåder med aloepolysaccharider
EP2714694A4 (en)	2014-11-05	BAKTERIOCHLORIMIDE